$166.2-252.5k
Plus pre-IPO equity and cash bonuses
Office located in Brisbane, CA
Biological analysis platform for cancer
Open for applications
Biological analysis platform for cancer
501-1000 employees
Open for applications
$166.2-252.5k
Plus pre-IPO equity and cash bonuses
Office located in Brisbane, CA
501-1000 employees
To reinvent disease management through early detection and precision intervention.
Desirable
Freenome is a biotechnology company offering a biological analysis platform that uses molecular biology and machine learning to detect cancer with a routine blood draw. The platform trains on thousands of cancer-positive blood samples to recognise disease-associated patterns and help detect early-stage cancer, allowing clinicians to optimise treatments.
The company specialises in advanced computational biology, using machine learning to detect patterns among billions of circulating cell-free biomarkers. Freenome continues to focus on the development of its colorectal cancer test, potentially helping the 45 million people not currently up-to-date on colorectal cancer screening guidelines in the United States.
Following its 2022 funding round, the company surpassed the $1 billion funding mark. Freenome is set to accelerate the development of its platform, testing for additional cancers and furthering its blood test detection technology. It's also forming partnerships for R&D purposes, joining forces with health firms such as Geisinger to provide real world data that could help it detect multiple cancers.
Steph
Company Specialist at Welcome to the Jungle
Feb 2024
$254m
LATE VC
Dec 2021
$300m
SERIES D
The East Side, South San Francisco, CA
Riley Ennis
(CPO)Studied at Yale, Johns Hopkins and Dartmouth. Was a Thiel Fellow and co-founded Immudicon and Oncolinx.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 3 more jobs at Freenome